IBN announces that Rob Etherington, President, Director and CEO of late clinical-stage biopharmaceutical company Clene, recently appeared on From Lab to Launch, a podcast sharing the inspiring stories of founders, investors, scientists, engineers and pioneers in the life sciences sector. The podcast, hosted by Meg Sinclair, is available for on-demand listening on From Lab to Launch. During the interview, Etherington discussed Clene’s work to address the critical unmet medical need relating to neurodegenerative diseases
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLNN:
- Clene Announces Breakthrough MS Therapy at Neurology Meeting
- Clene presents VISIONARY-MS long term extension study results
- Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
- Clene announces peer-reviewed publication on CNM-Au8
- Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®